Literature DB >> 20444753

Spondyloarthritis: state of the art and future perspectives.

Désirée van der Heijde1, Walter P Maksymowych.   

Abstract

Advances in the understanding of this group of arthritides over the past decade can be considered transformational from the perspective of basic mechanisms as well as clinical research focusing on the development of imaging technologies and a spectrum of standardised clinical outcomes that aim at a more comprehensive understanding of disease activity, functioning and disability, and prognosis. Prior to this decade, treatment was unsatisfactory and limited to physical modalities and non-steroidal anti-inflammatory agents, while diagnostic ascertainment primarily focused on clinical evaluation and plain radiography. Today, patients with spondyloarthritis (SpA) can look forward to earlier diagnosis and more effective treatment but significant challenges remain. This review will summarise the past decade's major accomplishments in the understanding of the basic mechanisms contributing to the development of SpA, outline those advances in clinical and imaging outcomes that have enabled major therapeutic advances and now permit a broader understanding of the early development of disease and its impact on patient well-being, and will describe new approaches to the development of diagnostic criteria that incorporate advances in imaging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444753     DOI: 10.1136/ard.2009.119529

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  7 in total

1.  Which clinical variables have the most significant correlation with quality of life evaluated by SF-36 survey in Croatian cohort of patient with ankylosing spondylitis and psoriatic arthritis?

Authors:  Zrinka Jajić; Ivana Rajnpreht; Nataša Kovačić; Ivan Krešimir Lukić; Vedran Velagić; Frane Grubišić; Ana Marušić; Danka Grčević
Journal:  Rheumatol Int       Date:  2011-11-08       Impact factor: 2.631

Review 2.  Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis.

Authors:  M L Stoll
Journal:  Clin Exp Rheumatol       Date:  2011-04-19       Impact factor: 4.473

3.  Effects of home-based exercise intervention on health-related quality of life for patients with ankylosing spondylitis: a meta-analysis.

Authors:  Hui Liang; Hua Zhang; Haiyan Ji; Chunmei Wang
Journal:  Clin Rheumatol       Date:  2015-03-15       Impact factor: 2.980

4.  High bone turnover assessed by 18F-fluoride PET/CT in the spine and sacroiliac joints of patients with ankylosing spondylitis: comparison with inflammatory lesions detected by whole body MRI.

Authors:  Dorothee R Fischer; Christian W A Pfirrmann; Veronika Zubler; Katrin D M Stumpe; Burkhardt Seifert; Klaus Strobel; Giorgio Tamborrini; Gustav K von Schulthess; Beat A Michel; Adrian Ciurea
Journal:  EJNMMI Res       Date:  2012-07-12       Impact factor: 3.138

5.  Real patient learning integrated in a preclinical block musculoskeletal disorders. Does it make a difference?

Authors:  Anne de Boer; Debbie Melchers; Sylvia Vink; Friedo Dekker; Liesbeth Beaart; Zuzana de Jong
Journal:  Clin Rheumatol       Date:  2011-02-24       Impact factor: 2.980

6.  Performance of 18F-sodium fluoride positron emission tomography with computed tomography to assess inflammatory and structural sacroiliitis on magnetic resonance imaging and computed tomography, respectively, in axial spondyloarthritis.

Authors:  Marie Raynal; Fehd Bouderraoui; Remy Ouichka; Julian Melchior; Olivier Morel; Alain Blum; Isabelle Chary-Valckenaere; Willy Ngueyon Sime; Véronique Roch; Walter Maksymowych; Robert G Lambert; Pierre Olivier; Damien Loeuille
Journal:  Arthritis Res Ther       Date:  2019-05-14       Impact factor: 5.156

7.  Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial.

Authors:  Caridad Pontes; Jordi Gratacós; Ferran Torres; Cristina Avendaño; Jesús Sanz; Antoni Vallano; Xavier Juanola; Eugenio de Miguel; Raimon Sanmartí; Gonzalo Calvo
Journal:  Trials       Date:  2015-08-20       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.